MEDICENNA THERAPEUTICS CORP(NASDAQ:MDNA) stock News

MDNA Latest News, Press Relases and Analysis

All

Press Releases

10 months ago - By: The Motley Fool - Mentions: JEPQ TSLA LRCX ORCL

1 High-Yield Dividend ETF to Buy to Generate Passive Income

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

2 years ago - By: InvestorPlace - Mentions: LUNR NVVE CDT

Dear LUNR Stock Fans, Mark Your Calendars for Jan. 12

2 years ago - By: InvestorPlace - Mentions: NVVE CDT MIRO

Why Is Medicenna Therapeutics (MDNA) Stock Down Today?

2 years ago - By: Benzinga - Mentions: CRKN NVVE MIRO BKYI ...

Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket

2 years ago - By: Benzinga

The Latest Analyst Ratings for Medicenna Therapeutics

2 years ago - By: InvestorPlace - Mentions: MIRO UTHR CDT IVCA ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Announces Nasdaq Delisting and Cutback of Management Team

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)

2 years ago - By: Seeking Alpha

Medicenna Therapeutics appoints Gardner as CMO (NASDAQ:MDNA)

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Announces Results of Annual and Special Meeting of Shareholders

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

2 years ago - By: Seeking Alpha

Medicenna Therapeutics gets new CFO (NASDAQ:MDNA)

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Presents at National Brain Tumor Society's Research Round Table

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Extends Period to Exercise Certain Warrants

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Announces Upcoming Presentation at the AACR Annual Meeting

2 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference

3 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Establishes At-the-Market Sales Facility

3 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights

3 years ago - By: Medicenna Therapeutics Corp. - Mentions: MDNA.CA

MEDICENNA THERAPEUTICS CORP (MDNA) Stock News

MDNA Latest News, Press Relases and Analysis

1 High-Yield Dividend ETF to Buy to Generate Passive Income

Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

Dear LUNR Stock Fans, Mark Your Calendars for Jan. 12

Why Is Medicenna Therapeutics (MDNA) Stock Down Today?

Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket

The Latest Analyst Ratings for Medicenna Therapeutics

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Medicenna Announces Nasdaq Delisting and Cutback of Management Team

Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors

Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)

Medicenna Therapeutics appoints Gardner as CMO (NASDAQ:MDNA)

Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

Medicenna Announces Results of Annual and Special Meeting of Shareholders

Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Medicenna Therapeutics gets new CFO (NASDAQ:MDNA)

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management

Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023

Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology

Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights

Medicenna Presents at National Brain Tumor Society's Research Round Table

Medicenna Extends Period to Exercise Certain Warrants

Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights

Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting

Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study

Medicenna Announces Upcoming Presentation at the AACR Annual Meeting

Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference

Medicenna Establishes At-the-Market Sales Facility

Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights

Medicenna to Present at the 2023 Guggenheim Oncology Conference